Depo-Provera is an injectable hormonal contraceptive that contains depot medroxyprogesterone acetate (DMPA), a long-acting form of the hormone progestin. It has been prescribed for decades to help prevent pregnancy by suppressing ovulation. While millions of people have used Depo-Provera, researchers continue studying its long-term safety profile, including whether prolonged use may be associated with an increased risk of meningioma, a typically slow-growing brain tumor.
Depo-Provera exposure occurs when an individual receives injections containing depot medroxyprogesterone acetate. Researchers studying long-term outcomes evaluate factors such as duration of use, cumulative exposure, dosage history, age, medical history, and other individual risk factors when assessing potential health effects.
Depo-Provera is administered as an injection approximately every three months, providing continuous hormonal contraception without requiring daily medication. Because the medication remains active in the body for an extended period, researchers have studied how prolonged exposure to synthetic progesterone may affect different tissues, including those that contain progesterone receptors.
Hormonal medications undergo extensive review before approval and continue to be monitored after they reach the market. As additional evidence becomes available, prescribing information and safety recommendations may be updated.
How Regulatory Agencies Review Hormonal Contraceptive Safety Data
Depo-Provera is available only by prescription, and healthcare providers evaluate each patient's medical history before recommending its use. Factors such as previous medical conditions, pregnancy plans, bone health, and other contraceptive options may influence treatment decisions.
Healthcare providers also continue monitoring patients throughout treatment and discuss known risks, benefits, and any new safety information that becomes available over time.
Researchers continue studying why some individuals develop meningiomas while many others with similar medication histories do not.
Factors commonly evaluated include:
Current research suggests that multiple factors may contribute to an individual's overall risk, and researchers continue investigating how these variables may interact.
Researchers are studying whether long-term use of Depo-Provera may be associated with a higher risk of meningioma, especially after prolonged exposure. Research is still developing, but recent studies, regulatory reviews, and meningioma treatment advances have brought new attention to how hormonal medications, tumor biology, and patient risk factors may overlap.
A 2024 French population-based study and a 2025 JAMA Neurology study both reported associations between injectable DMPA and meningioma, with the JAMA study noting higher relative risk after more than four years of use or when treatment began after age 31. Meningioma research is also advancing through tumor genetics and targeted treatment studies, including a 2026 Nature Medicine trial studying abemaciclib for recurrent grade 2 and 3 meningiomas.
Meningiomas are the most commonly diagnosed primary brain tumors in adults and occur more frequently in women than in men. Most are benign and slow-growing, although their location can still result in significant neurological symptoms.
It is important to note that recent Depo-Provera studies have reported increased relative risk, but the absolute risk remains low.
Meningioma treatment research is moving toward more personalized care. Newer approaches include molecular profiling, advanced imaging, stereotactic radiotherapy, targeted agents, immune checkpoint inhibitors, and targeted radioligand therapy for certain recurrent or aggressive tumors. Researchers are also studying targeted therapies for higher-grade or recurrent meningiomas, where treatment options may be limited after surgery and radiation.
Researchers continue studying new approaches to diagnosing and treating meningiomas, including advanced imaging, targeted therapies, immunotherapy, precision medicine, surgical techniques, radiation therapy, and quality-of-life outcomes.
Individuals interested in learning more about active clinical trials can search resources maintained by the Mayo Clinic, UCSF, UC San Diego, and Power, which regularly update their listings as new studies become available.
Patients should discuss potential clinical trial participation with their healthcare team to determine whether a study may be appropriate for their diagnosis and treatment history.
Anyone considering Depo-Provera should discuss its benefits and potential risks with their healthcare provider. Treatment decisions should always be individualized based on medical history, contraceptive goals, and current scientific evidence.
Depo-Provera should only be used under the supervision of a qualified healthcare provider. Patients should review the prescribing information, discuss any changes in their medical history, and attend recommended follow-up appointments throughout treatment.
Because medication safety information evolves as new research becomes available, patients should also stay informed about updated prescribing recommendations and discuss any concerns with their healthcare team before making changes to their treatment.
Many people use Depo-Provera without developing serious health problems. However, persistent neurological symptoms should always be evaluated by a healthcare provider.
Potential warning signs include:
These symptoms do not necessarily indicate a meningioma but warrant medical evaluation to determine the underlying cause.
Depo-Provera has remained under ongoing regulatory review since its approval, with its safety profile continuing to be evaluated through post-market surveillance, published research, adverse event reporting, and manufacturer data. In December 2025, the U.S. Food and Drug Administration (FDA) approved an update to Depo-Provera's prescribing information to include information about the risk of meningioma, following review of emerging scientific evidence and recommendations from the European Medicines Agency (EMA). Regulatory agencies continue monitoring new research and may update prescribing information or other safety communications as additional evidence becomes available.
How Regulatory Agencies Review Hormonal Contraceptive Safety Data
Prescription medications are subject to continuing safety oversight after approval. Manufacturers, healthcare professionals, researchers, and regulatory agencies all contribute to monitoring medication safety through adverse event reporting, post-market studies, and ongoing clinical research. The process helps identify potential safety signals that may not have been apparent during pre-approval clinical trials.
Individuals diagnosed with meningioma after prolonged Depo-Provera use may wish to better understand their legal options. Eligibility depends on the individual's medical history, medication history, and the specific facts surrounding each case.
Individuals considering a Depo-Provera claim generally may need documentation regarding:
Eligibility varies based on individual circumstances and applicable law.
Potential compensation may include:
Available compensation depends on the facts of each claim.
The deadline for filing a Depo-Provera-related claim varies by state. Filing deadlines may depend on when an injury was diagnosed, when it was reasonably discovered, and other state-specific legal requirements.
Documentation that may be helpful includes:
Maintaining complete medical documentation may help establish treatment history and diagnosis.
Depo-Provera litigation is in its early stages, with thousands of women filing lawsuits alleging they developed meningioma after prolonged use of the medication. Many federal cases have been consolidated into multidistrict litigation (MDL) in the U.S. District Court for the Northern District of Florida to streamline pretrial proceedings. The court has selected Toney v. Pfizer Inc. as the first bellwether case, which is expected to help evaluate evidence and legal arguments that may shape future proceedings. Because the litigation is ongoing, no bellwether verdicts have been issued, and each case will be decided based on its own facts and evidence.
© 2026, Injury Info. All rights reserved.